Divesiran (SLN124) - (SANRECO)

June 11, 2026: Silence Therapeutics plc (NASDAQ: SLN) presented follow-up and quality-of-life data at the European Hematology Association (EHA) 2026 Annual Congress from the Phase 1 SANRECO study of divesiran, a first-in-class siRNA targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV).

Key Phase 1 findings reported: phlebotomy requirements fell from 80 total procedures in the six months pre-treatment to 5 during active treatment (all in patients “uncontrolled” at baseline with hematocrit >45%), and to 4 during the 16-week post–final dose follow-up, suggesting durability after dosing stopped. In 14 patients with additional follow-up, median time to first phlebotomy was 287 days. Most patients improved on MPN-10 total symptom scores through Week 34. Divesiran was described as well tolerated, with no dose-limiting toxicities; most common TEAEs were mild, transient injection-site reactions, with no treatment-related serious AEs or discontinuations.

Upcoming catalyst: the ongoing randomized, placebo-controlled Phase 2 SANRECO trial (NCT05499013) testing 6 mg Q6W vs Q12W dosing in 48 patients remains on track, with topline data expected in August 2026.